|
1
|
DeFronzo RA: Banting Lecture. From the
triumvirate to the ominous octet: a new paradigm for the treatment
of type 2 diabetes mellitus. Diabetes. 58:773–795. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferrannini E, Gastaldelli A, Miyazaki Y,
Matsuda M, Mari A and DeFronzo RA: β-Cell function in subjects
spanning the range from normal glucose tolerance to overt diabetes
mellitus: a new analysis. J Clin Endocrinol Metab. 90:493–500.
2005.
|
|
3
|
Abdul-Ghani MA, Tripathy D and DeFronzo
RA: Contribution of β-cell dysfunction and insulin resistance to
the pathogenesis of impaired glucose tolerance and impaired fasting
glucose. Diabetes Care. 29:1130–1139. 2006.
|
|
4
|
Abdul-Ghani MA, Jenkinson CP, Richardson
DK, Tripathy D and DeFronzo RA: Insulin secretion and insulin
action in subjects with impaired fasting glucose and impaired
glucose tolerance: results from the Veterans Administration Genetic
Epidemiology Study. Diabetes. 55:1430–1435. 2006. View Article : Google Scholar
|
|
5
|
Weyer C, Tataranni PA, Bogardus C and
Pratley RE: Insulin resistance and insulin secretory dysfunction
are independent predictors of worsening of glucose tolerance during
each stage of type 2 diabetes development. Diabetes Care. 24:89–94.
2001. View Article : Google Scholar
|
|
6
|
Jallut D, Golay A, Munger R, Frascarolo P,
Schutz Y, Jéquier E and Felber JP: Impaired glucose tolerance and
diabetes in obesity: a 6-year follow-up study of glucose
metabolism. Metabolism. 39:1068–1075. 1990.PubMed/NCBI
|
|
7
|
Altshuler D, Hirschhorn JN, Klannemark M,
et al: The common PPARgamma Pro12Ala polymorphism is associated
with decreased risk of type 2 diabetes. Nat Genet. 26:76–80. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rissanen J, Markkanen A, Kärkkäinen P, et
al: Sulfonylurea receptor 1 gene variants are associated with
gestational diabetes and type 2 diabetes but not with altered
secretion of insulin. Diabetes Care. 23:70–73. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hara K, Okada T, Tobe K, et al: The
Pro12Ala polymorphism in PPARγ2 may confer resistance to type 2
diabetes. Biochem Biophys Res Commu. 271:212–216. 2000.
|
|
10
|
Chang TC and Mendell JT: microRNAs in
vertebrate physiology and human disease. Annu Rev Genomics Hum
Genet. 8:215–239. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Poy MN, Eliasson L, Krutzfeldt J, et al: A
pancreatic islet-specific microRNA regulates insulin secretion.
Nature. 432:226–230. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Baroukh N, Ravier MA, Loder MK, et al:
MicroRNA-124a regulates Foxa2 expression and intracellular
signaling in pancreatic β-cell lines. J Biol Chem. 282:19575–19588.
2007.PubMed/NCBI
|
|
13
|
Joglekar MV, Parekh VS, Mehta S, Bhonde RR
and Hardikar AA: MicroRNA profiling of developing and regenerating
pancreas reveal post-transcriptional regulation of neurogenin3. Dev
Biol. 311:603–612. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Plaisance V, Abderrahmani A, Perret-Menoud
V, Jacquemin P, Lemaigre F and Regazzi R: MicroRNA-9 controls the
expression of Granuphilin/Slp4 and the secretory response of
insulin-producing cells. J Biol Chem. 281:26932–26942. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tang X, Muniappan L, Tang G and Ozcan S:
Identification of glucose-regulated miRNAs from pancreatic β cells
reveals a role for miR-30d in insulin transcription. RNA.
15:287–293. 2009.PubMed/NCBI
|
|
16
|
Lynn FC, Skewes-Cox P, Kosaka Y, McManus
MT, Harfe BD and German MS: MicroRNA expression is required for
pancreatic islet cell genesis in the mouse. Diabetes. 56:2938–2945.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Temple IK, Gardner RJ, Mackay DJ, Barber
JC, Robinson DO and Shield JP: Transient neonatal diabetes:
widening the understanding of the etiopathogenesis of diabetes.
Diabetes. 49:1359–1366. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Report of a WHO Consultation: Definition,
Diagnosis and Classification of Diabetes Mellitus and its
complications: Report of a WHO Consultation 1999. Part 1: Diagnosis
and classification of diabetes mellitus. 1–65. 1999.
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
|
|
20
|
Poy MN, Hausser J, Trajkovski M, et al:
miR-375 maintains normal pancreatic alpha- and beta-cell mass. Proc
Natl Acad Sci USA. 106:5813–5818. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xia HQ, Pan Y, Peng J and Lu GX:
Over-expression of miR375 reduces glucose-induced insulin secretion
in Nit-1 cells. Mol Bio Rep. 38:3061–3065. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
El Ouaamari A, Baroukh N, Martens GA,
Lebrun P, Pipeleers D and van Obberghen E: miR-375 targets
3′-phosphoinositide-dependent protein kinase-1 and regulates
glucose-induced biological responses in pancreatic β-cells.
Diabetes. 57:2708–2717. 2008.
|
|
23
|
de Souza Rocha Simonini P, Breiling A,
Gupta N, et al: Epigenetically deregulated microRNA-375 is involved
in a positive feedback loop with estrogen receptor alpha in breast
cancer cells. Cancer Res. 70:9175–9184. 2010.PubMed/NCBI
|
|
24
|
Ding L, Xu Y, Zhang W, et al: MiR-375
frequently downregulated in gastric cancer inhibits cell
proliferation by targeting JAK2. Cell Res. 20:784–793. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun K, Chang XY, Yin L, et al: Expression
and DNA methylation status of microRNA-375 in patients with type 2
diabetes mellitus. Mol Med Rep. 9:967–972. 2014.PubMed/NCBI
|
|
26
|
Reid G, Métivier R, Lin CY, et al:
Multiple mechanisms induce transcriptional silencing of a subset of
genes, including oestrogen receptor alpha, in response to
deacetylase inhibition by valproic acid and trichostatin A.
Oncogene. 24:4894–4907. 2005. View Article : Google Scholar
|
|
27
|
Kangaspeska S, Stride B, Métivier R, et
al: Transient cyclical methylation of promoter DNA. Nature.
452:112–115. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Métivier R, Gallais R, Tiffoche C, et al:
Cyclical DNA methylation of a transcriptionally active promoter.
Nature. 452:45–50. 2008.PubMed/NCBI
|
|
29
|
Maier S and Olek A: Diabetes: a candidate
disease for efficient DNA methylation profiling. J Nutr. 132(Suppl
8): 2440S–2443S. 2002.PubMed/NCBI
|
|
30
|
Barrès R, Osler ME, Yan J, et al: Non-CpG
methylation of the PGC-1alpha promoter through DNMT3B controls
mitochondrial density. Cell Metab. 10:189–198. 2009.PubMed/NCBI
|
